🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?

Inside Boston Scientific's 0.71 PEG Ratio, $3.7 Billion Free Cash Flow Machine, and Why This MedTech Giant May Be One of 2026's Most Overlooked GARP Opportunities

🫀 After a brutal valuation collapse, CEO Mike Mahoney bought the dip. We examine the insider conviction, institutional ownership, FARAPULSE moat, valuation, risks, and whether BSX deserves a place in a long-term portfolio after the guidance reset 🫀🔥

Boston Scientific

$47.74
-1.35 
(-2.75%)
As of Aug. 5, 2026, 4:10 PM ET

🚀 Quick Take (TL;DR)

Sometimes Mr. Market gets emotional.

Boston Scientific didn't report collapsing sales.

It didn't lose money.

Its products didn't suddenly stop working.

Hospitals didn't stop treating heart disease.

Instead, after a long bear at the end of which (cherry on top) management modestly reduced its forward guidance—Wall Street responded by slicing more than half off the company's valuation from its 2025 peak.

Then something interesting happened.

CEO Mike Mahoney reached into his own pocket and bought roughly $9 million worth of Boston Scientific shares.

Not options.

Not restricted stock.

Cold, hard cash.

When the person with the deepest understanding of the business buys aggressively after a selloff, long-term investors should at least pause before joining the panic.

🫀 Executive Summary

At FUNanc1al, we're fascinated by situations where price and business quality temporarily part ways.

Boston Scientific may be one of those situations.

Yes, management lowered near-term guidance.

But beneath the headlines remains a company that:

• generated $20.1 billion in FY2025 revenue
• produced roughly $3.7 billion in free cash flow
• expanded operating margins
• continues to dominate several fast-growing cardiovascular markets
• trades at a forward P/E under 15
• sports a remarkably low 0.71 PEG ratio
• is owned almost entirely by sophisticated institutional investors
• just saw its CEO personally invest $9 million in additional shares.

That's not a broken business.

That's a business the market may have temporarily misdiagnosed.

💬 FUNanc1al Atomic Statement #1

Markets routinely confuse slower growth with broken businesses. Long-term investors shouldn't.

🩺 Trigger #1: A $9 Million Vote of Confidence

Executives know more about their businesses than any outside analyst ever will.

That doesn't mean every insider purchase predicts future gains.

It does mean that large, open-market purchases deserve attention—especially after a sharp selloff.

On August 3, CEO Mike Mahoney purchased approximately 186,000 shares, investing just over $9 million of his own money at around $48.33 per share. Director David Habiger joined him with an additional purchase.

This wasn't symbolic.

This wasn't a token purchase designed to make headlines.

Mahoney increased his ownership by roughly 13%, bringing his holdings to more than 1.6 million shares.

Context matters.

Mahoney has spent decades leading major medical technology businesses, including senior leadership roles at Johnson & Johnson and General Electric Healthcare before becoming Boston Scientific's CEO in 2012.

People with that résumé rarely make impulsive nine-million-dollar decisions.

Especially after earnings.

Especially when everyone else is selling.

📊 Trigger #2: Wall Street Hasn't Lost Faith

One statistic immediately caught our attention.

Institutional investors own more than 96% of Boston Scientific's float.

Think about that for a moment.

Nearly every available share is already sitting inside the portfolios of pension funds, asset managers, insurance companies, mutual funds, quantitative strategies, and hedge funds.

Among the largest owners are names every investor recognizes:

• BlackRock
• Vanguard
• Fidelity
• State Street
• JPMorgan
• D.E. Shaw

These firms collectively manage trillions of dollars and employ armies of analysts, physicians, engineers, statisticians, and industry specialists.

Could they all be wrong?

Of course.

But when institutions remain overwhelmingly invested after a guidance reset—and the CEO simultaneously buys millions of dollars' worth of stock—it becomes increasingly difficult to argue that Boston Scientific is facing an existential crisis.

Even more interesting?

Short sellers don't seem interested either.

Only about 1.96% of the float is sold short, with approximately 1.35 days to cover.

There's little chance of a dramatic short squeeze.

But there's also remarkably little evidence that sophisticated investors believe the business deserves to trade substantially lower.

Sometimes, what isn't happening is just as informative as what is.

For Boston Scientific (BSX)’s Institutional Ownership breakdown, 🔍 see here.

❤️ Trigger #3: The Business Is Still Beating

Here's where the narrative starts to diverge from the headlines.

Boston Scientific's second-quarter numbers were hardly disastrous.

Revenue climbed to roughly $5.44 billion, increasing 7.5% year over year.

Adjusted EPS came in at $0.86, comfortably ahead of consensus expectations.

Operating margin expanded to 21.6%, up significantly from the prior year.

Those aren't the financials of a company in decline.

The issue wasn't the quarter.

It was the outlook.

Management reduced its full-year expectations as certain businesses—including WATCHMAN and parts of electrophysiology—experienced slower-than-anticipated momentum.

Markets often react violently to lowered guidance because valuation models are forward-looking.

That's understandable.

But there's an important distinction between slower growth and negative growth.

Boston Scientific still expects to grow.

It simply expects to grow a little less quickly than previously forecast.

That's an entirely different diagnosis.

Meanwhile, the innovation engine keeps humming.

The company continues advancing its FARAPULSE™ Pulsed Field Ablation platform, expanding the FARAFLEX™ clinical program, investing in next-generation structural heart technologies, and deploying capital through strategic investments and acquisitions.

Healthcare innovation rarely follows a straight line.

Neither do great compounders.

👉 Want the full picture? Dive into Boston Scientific (BSX)'s financials here.

💬 FUNanc1al Atomic Statement #2

When a world-class business gets cheaper while management gets more confident, investors should pay attention—not panic.

💰 Trigger #4: Valuation Finally Looks Interesting

Great companies don't always make great investments.

Valuation matters.

And this is where Boston Scientific becomes particularly intriguing.

Today the shares trade around:

• Forward P/E: 14.9x
• PEG Ratio: 0.71
• EV/EBITDA: 14.8x
• Price-to-Sales: 3.5x
• Annual Free Cash Flow: roughly $3.7 billion

Let's pause on that PEG ratio.

Many investors consider a PEG below 1.0 to indicate that expected earnings growth more than compensates for the current valuation multiple.

No single metric should ever drive an investment decision.

But when a company with dominant franchises, strong free cash flow, expanding margins, and industry-leading technology trades at 0.71 PEG, it's difficult not to investigate further.

Another interesting observation?

The stock still sits roughly 56% below its 2025 all-time high.

Markets don't always return to previous highs.

But history repeatedly shows that valuation compression often creates opportunity—particularly when the underlying business remains fundamentally healthy.

🎭 A Dash of FUNanc1al Humor

Apparently Wall Street diagnosed Boston Scientific with a common cold...

...and priced it as though it needed open-heart surgery.

Meanwhile, the CEO quietly walked into the pharmacy and spent $9 million on the company's own prescription.

📈 Trigger #5: The Market May Be Missing the Forest for the Trees

Every earnings season, Wall Street asks essentially the same question:

"Did the company beat expectations?"

Long-term investors should be asking something slightly different:

"Has the long-term investment thesis changed?"

In Boston Scientific's case, the answer appears to be not materially.

The company still generates more than $20 billion in annual revenue, approximately $3.7 billion in annual free cash flow, enjoys gross margins approaching 70%, continues investing aggressively in innovation, and remains one of the world's dominant cardiovascular device manufacturers.

The guidance reset certainly deserves attention.

But guidance changes are temporary.

Competitive advantages are far more durable.

Boston Scientific continues to strengthen its leadership in electrophysiology through FARAPULSE™, one of the most closely watched platforms in pulsed field ablation (PFA). Clinical data released throughout 2026 remained encouraging, while additional catheter platforms and structural heart investments continue expanding the company's competitive moat.

This isn't a company cutting research to survive.

It's a company investing heavily because it believes tomorrow will be larger than today.

That distinction matters.

⚠️ Risk Calibration

No investment is risk-free.

Boston Scientific isn't either.

Several risks deserve monitoring:

🔸 Guidance credibility

Management lowered 2026 expectations.

If future revisions continue moving downward, investor confidence could weaken further.

🔸 Competitive pressure

Johnson & Johnson, Medtronic and other global medtech leaders are investing aggressively in electrophysiology and structural heart technologies.

Innovation leadership can never be taken for granted.

🔸 Procedure volumes

WATCHMAN and several cardiovascular franchises experienced softer-than-expected demand in certain regions.

Should those trends persist, valuation could remain compressed longer than investors expect.

🔸 Healthcare reimbursement

Medical device companies ultimately depend upon hospitals, physicians, insurers and government reimbursement systems.

Changes in reimbursement policy always deserve attention.

Fortunately, none of these risks currently suggest Boston Scientific's competitive position is permanently impaired.

They simply remind investors that even wonderful businesses experience difficult quarters.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

🏆 The FUNanc1al Verdict

Sometimes the market creates opportunities by confusing uncertainty with permanent impairment.

Boston Scientific increasingly looks like one of those situations.

After a sharp correction, investors can now purchase a global MedTech leader at:

• a Forward P/E below 15
• a PEG Ratio of only 0.71
• approximately $3.7 billion of annual free cash flow
• expanding operating margins
• dominant positions across several cardiovascular categories
• nearly 96% institutional ownership
• and perhaps most importantly...

...a CEO who just invested $9 million of his own capital after the selloff.

That's a combination we don't see very often.

Could shares fall further?

Absolutely.

Markets rarely ring a bell at the bottom.

But for patient investors willing to think in years rather than quarters, Boston Scientific increasingly resembles a classic GARP (Growth At a Reasonable Price) opportunity.

Not spectacularly cheap.

Not outrageously expensive.

Simply a high-quality compounder that Mr. Market may have temporarily put on clearance.

🚀 FUNanc1al Atomic Statement #3

Exceptional companies rarely become cheap without a reason. Exceptional investments happen when that reason proves temporary.

📌 Signal Extract

Markets routinely confuse slower growth with broken businesses. Long-term investors shouldn't.

🎯 High-Conviction Takeaway

When a world-class business gets cheaper while management gets more confident, investors should pay attention—not panic.

❓Frequently Asked Questions

Is Boston Scientific a value stock?

Not in the traditional sense.

It remains primarily a growth company, but today's valuation increasingly resembles that of a value investment. That's precisely why we view BSX as an attractive GARP opportunity.

Why is the CEO purchase important?

Executives sell shares for countless personal reasons.

Large open-market purchases are much rarer.

A $9 million purchase represents meaningful financial commitment and suggests management believes the market has become overly pessimistic.

Is the guidance cut a major concern?

It deserves monitoring.

However, reduced growth expectations are not the same as deteriorating fundamentals.

Revenue, margins, cash generation and innovation remain healthy.

What stands out most?

Probably the combination of:

• CEO conviction
• 96% institutional ownership
• low short interest
• strong free cash flow
• a sub-1 PEG ratio
• and category-leading cardiovascular technology.

Rarely do all six appear simultaneously.

Who might like BSX?

Long-term investors seeking a balance between growth and value.

Income investors probably won't find much excitement here.

Compounders likely will.

🍽️ Food for Thought: The Cross-Hub Connection

Healthcare innovation reminds us of something broader.

The greatest breakthroughs often arrive quietly.

Years of research.

Thousands of failed experiments.

Countless clinical trials.

Then suddenly...

One technology meaningfully improves human lives.

Investing works much the same way.

Exceptional returns rarely come from chasing headlines.

They come from patiently owning businesses that continue improving while the market temporarily looks elsewhere.

Whether discussing medicine, entrepreneurship or life itself, durable progress usually compounds long before it becomes obvious.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al—part market analyst, part storyteller, part accidental comedian.

A longtime investor, entrepreneur, and venture-builder across technology, biotech, and fintech, he combines rigorous research with behavioral finance and a touch of humor to help readers laugh, learn, live better lives, and invest a little wiser.

When he isn't decoding insider purchases or poking fun at earnings calls, he's building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

📝 Editorial Note

Every FUNanc1al article is grounded in human research, analysis, and editorial judgment. Modern AI tools may assist with research organization, editing, and presentation, but every opinion, conclusion, rating, and recommendation remains subject to human oversight and responsibility.

To learn more about how we research, write, and review every article, please visit our Editorial Process page.

At FUNanc1al, our objective is not to predict the future with certainty, but to encourage thoughtful analysis, healthy skepticism, long-term thinking, and a smile whenever possible.